The question of whether MiniMed Group, Inc. (MMED) can climb to $25 turns on how quickly the recently spun-off diabetes technology company can convert strong revenue growth into sustained profitability. The shares, which began trading on the Nasdaq Global Select Market in March 2026 following an initial public offering carved out of Medtronic plc (MDT), closed near $17.49 in mid-October 2026. A move to $25 would require roughly a 43% advance, a very large step for a business still digesting the costs of operating as an independent public company.
MiniMed is a stock with substantial analyst coverage. Averaging the most recent individually reported price targets from firms including Rothschild & Co Redburn ($30), Truist ($29), BTIG, Mizuho, UBS and Bank of America (each $28), Evercore ISI ($27), Citigroup and Wells Fargo (each $26), Jefferies and Barclays (each $22), Morgan Stanley ($21), Benchmark ($20) and Piper Sandler ($16) produces a mean near $25. The low-to-high range of roughly $16 to $30 is notably wide, signaling that bullish and cautious analysts disagree more on valuation and competitive positioning than on the basic direction of the business.
The overall tone is constructive, with most ratings carrying a Buy or Outperform designation and a smaller group of Hold and Equal-Weight views. Following better-than-expected fiscal first-quarter results reported in September 2026, several firms raised targets, with Mizuho citing upside versus "conservative" guidance and BTIG pointing to pipeline milestones arriving ahead of schedule. Cautious voices focus on profitability: adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin was roughly 9.9% in that quarter, and free cash flow was negative as separation costs weighed on results. The $25 average analyst price target is a calculated figure, not an official published consensus, and should be read as a central tendency rather than a guarantee.
At about $17.49, MiniMed trades well below its 52-week high of $24.43 and above its 52-week low of $10.65, with a market capitalization near $4.9 billion. The stock is unprofitable on a trailing basis, so conventional earnings-based valuation measures do not apply cleanly; investors are effectively paying for future margin expansion and continued market-share gains. Reaching $25 would require a roughly 43% move, which is a very large appreciation for a newly independent company. The path would most plausibly run through sustained double-digit revenue growth, margin improvement as one-time separation costs roll off, and successful launches of next-generation products.
The fundamental case rests on momentum in the core diabetes franchise. In the quarter ended July 31, 2026, worldwide net sales rose about 16.6% to $843 million, U.S. sales grew roughly 13%, and management raised full-year organic revenue growth guidance to approximately 10.5%. New pump sales in the U.S. climbed more than 20% year over year, and the company's global continuous glucose monitor (CGM) attachment rate reached about 69%. The pipeline is advancing on multiple fronts: the MiniMed Fit patch pump has been submitted to the U.S. Food and Drug Administration, MiniMed Flex received a CE Mark in Europe, and enrollment in the Vivera closed-loop algorithm trial has been completed. Completing the separation from Medtronic in October 2026 removes a structural overhang and lets management operate with greater focus.
The principal obstacle is profitability. Free cash flow was negative in the most recent quarter, with roughly $111 million of separation and stand-up costs, and only a small fraction of the transition service agreements with Medtronic have been exited so far. Competition is also formidable: MiniMed faces Abbott and Dexcom in continuous glucose monitoring and Tandem Diabetes and Insulet in insulin pumps, all of which can pressure pricing and attachment rates. The wide $16-to-$30 analyst range reflects this uncertainty, and the lowest targets embed the risk that margin recovery takes longer than bulls expect. Any slowdown in U.S. growth or delays in new product launches could compress the valuation that underpins the higher targets.
The shares sit below their 50-day moving average near $20.53, which now acts as an initial resistance zone, with the 52-week high of $24.43 representing the next significant hurdle just beneath the $25 objective. On the downside, the 200-day moving average near $16.50 and the 52-week low of $10.65 mark support levels. Because the stock has traded as high as $24.43 since its IPO, $25 is not an untested price area, but it would still require reclaiming the recent range's upper boundary and holding above it.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ, and MiniMed's short public history makes any long-run assumptions provisional. Investors should watch quarterly earnings and guidance, progress exiting Medtronic transition service agreements, margin and free-cash-flow trends, FDA and CE Mark decisions for the Fit and Flex products, and CGM attachment rates. Competitive pricing moves from Abbott, Dexcom, Tandem and Insulet, along with any analyst target revisions, will also shape the market's view of whether $25 is reachable.
Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and identify shifting trends more efficiently than manual review allows. For a newly listed name like MiniMed, where price history is short and volatility can be elevated, pairing analyst targets with AI-generated signals can help filter noise and flag momentum changes. Explore the AI Daily Buy/Sell Signals to see how automated analysis frames opportunities across the market.
Whether MiniMed can reach $25 depends on execution rather than demand, which has been robust. The roughly 43% upside implied by the average analyst price target reflects confidence in double-digit revenue growth and an advancing product pipeline, offset by legitimate concerns about margins, cash flow, and competition. The wide $16-to-$30 target range shows that even professional forecasts diverge sharply on valuation. Investors monitoring earnings, separation costs, and product milestones will get the clearest read on whether the stock can sustain a move toward the $25 average analyst price target. No outcome is assured, and the target is a research benchmark, not a prediction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.